Asked by: John Glen (Conservative - Salisbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to improve (a) levels of access to and (b) the quality of (i) palliative and (ii) end of life care across England.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
Palliative care services are included in the list of services an integrated care board (ICB) must commission. To support ICBs in this duty, NHS England has published statutory guidance and service specifications. The statutory guidance states that ICBs must work to ensure that there is sufficient provision of care services to meet the needs of their local populations
NHS England has also developed a palliative care and end of life care dashboard, which brings together all relevant local data in one place. The dashboard helps commissioners understand the palliative care and end of life care needs of their local population, enabling ICBs to put plans in place to address and track the improvement of health inequalities, and ensure that funding is distributed fairly, based on prevalence.
The Department and NHS England are currently looking at how to improve the access, quality, and sustainability of all-age palliative care and end of life care in line with the 10-Year Health Plan.
We will closely monitor the shift towards the strategic commissioning of palliative care and end of life care services to ensure that services reduce variation in access and quality, although some variation may be appropriate to reflect both innovation and the needs of local populations.
Additionally, through the National Institute for Health and Care Research, the Department is investing £3 million in a Policy Research Unit in Palliative and End of Life Care. This unit, launched in January 2024, is building the evidence base on palliative care and end of life care, with a specific focus on inequalities.
Whilst the majority of palliative care and end of life care is provided by National Health Service staff and services, we recognise the vital part charitable hospices play as well. This is why we are supporting the hospice sector with a £100 million capital funding boost for eligible adult and children’s hospices in England to ensure they have the best physical environment for care.
We are also providing £26 million in revenue funding to support children and young people’s hospices for 2025/26. I am pleased to confirm the continuation of this vital funding for the next three financial years, from 2026/27 to 2028/29 inclusive. This funding will see approximately £26 million, adjusted for inflation, allocated to children and young people’s hospices in England each year, via their local ICBs on behalf of NHS England, as happened in 2024/25 and 2025/26. This amounts to approximately £80 million over the next three years.
Asked by: John Glen (Conservative - Salisbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what progress he has made on improving (a) access to, (b) quality of and (c) sustainability of (i) palliative care and (ii) end of life care for people of all ages through the 10 Year Health Plan, published on 3 July 2025.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
Palliative care services are included in the list of services an integrated care board (ICB) must commission. To support ICBs in this duty, NHS England has published statutory guidance and service specifications. The statutory guidance states that ICBs must work to ensure that there is sufficient provision of care services to meet the needs of their local populations.
NHS England has also developed a palliative care and end of life care dashboard, which brings together all relevant local data in one place. The dashboard helps commissioners understand the palliative care and end of life care needs of their local population, enabling ICBs to put plans in place to address and track the improvement of health inequalities, and ensure that funding is distributed fairly, based on prevalence.
The Department and NHS England are currently looking at how to improve the access, quality, and sustainability of all-age palliative care and end of life care in line with the 10-Year Health Plan.
We will closely monitor the shift towards the strategic commissioning of palliative care and end of life care services to ensure that services reduce variation in access and quality, although some variation may be appropriate to reflect both innovation and the needs of local populations.
Additionally, through the National Institute for Health and Care Research, the Department is investing £3 million in a Policy Research Unit in Palliative and End of Life Care. This unit, launched in January 2024, is building the evidence base on palliative care and end of life care, with a specific focus on inequalities.
Whilst the majority of palliative care and end of life care is provided by National Health Service staff and services, we recognise the vital part charitable hospices play as well. This is why we are supporting the hospice sector with a £100 million capital funding boost for eligible adult and children’s hospices in England to ensure they have the best physical environment for care.
We are also providing £26 million in revenue funding to support children and young people’s hospices for 2025/26. I am pleased to confirm the continuation of this vital funding for the next three financial years, from 2026/27 to 2028/29 inclusive. This funding will see approximately £26 million, adjusted for inflation, allocated to children and young people’s hospices in England each year, via their local ICBs on behalf of NHS England, as happened in 2024/25 and 2025/26. This amounts to approximately £80 million over the next three years.
Asked by: John Glen (Conservative - Salisbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 23 July 2025 to Question 68387 on Epilepsy and Pregnancy: Sodium Valproate, what his Departments planned timeline is for establishing a centralised register caputring Pregnancy Prevention Programme interventions and acknowledgements, linked to prescribing data.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
NHS England has worked collaboratively with the Medicines and Healthcare products Regulatory Agency on the safer use of valproate containing medicines. The best way to a centralised register is through the single patient record and the use of this to populate the federated data platfor, which would allow for the functionality of a centralised register. This is enabled by the Transformation Directorate to ensure that clinical care can be effectively and accurately coded.
The Medicines and Pregnancy Register monitors prescribing of valproate and highlights the number of pregnancies potentially exposed to valproate. This data demonstrates a reduction in prescribing valproate to women and girls as well as a reduction in the number of possible exposed pregnancies since the Pregnancy Prevention Programme (PPP) was introduced in 2018. Analysis shows the implementation of the PPP by ICBs is consistent across the country. The register is available at the following link:
Asked by: John Glen (Conservative - Salisbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 23 July 2025 to Question 68387 on Epilepsy and Pregnancy: Sodium Valproate, what steps his Department is taking to ensure (a) consistent and (b) effective implementation of the Pregnancy Prevention Programme by Integrated Care Boards.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
NHS England has worked collaboratively with the Medicines and Healthcare products Regulatory Agency (MHRA) on the safer use of valproate containing medicines and there have been several steps to ensure that integrated care boards (ICBs) lead the implementation of the regulations set out by the MHRA. The agency issued a National Patient Safety Alert on valproate in November 2023, which is available at the following link:
The Medicines and Pregnancy Register monitors prescribing of valproate and highlights the number of pregnancies potentially exposed to valproate. This data demonstrates a reduction in prescribing valproate to women and girls as well as a reduction in the number of possible exposed pregnancies since the Pregnancy Prevention Programme (PPP) was introduced in 2018. Analysis shows the implementation of the PPP by ICBs is consistent across the country. The register is available at the following link:
Other information available to patients, clinical practitioners and prescribers includes: information from the MHRA; Decision Support Tools and Patient Information leaflets issued by NHS England; and the Valproate Integrated Quality Improvement Programme offered by NHS England. These are available at the following links:
https://www.gov.uk/guidance/valproate-reproductive-risks
https://www.england.nhs.uk/personalisedcare/shared-decision-making/decision-support-tools/
https://www.southeastclinicalnetworks.nhs.uk/our-networks/valproate/
https://www.england.nhs.uk/patient-safety/sodium-valproate/
Asked by: John Glen (Conservative - Salisbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many NHS employees with a declared terminal diagnosis die when in (a) employment and (b) retirement.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Whilst the Department does not hold the information requested, it does hold information on the number of National Health Service staff applications for NHS pension benefits on the grounds of serious ill-health. These pensions may be paid where members of the NHS Pension Scheme are terminally ill and have a life expectancy of less than 12 months.
The following table shows the number of applications for serious ill-health pensions accepted by the scheme administrator, the NHS Business Services Authority (NHSBSA), for the last five complete scheme years, and is correct as of 2 September 2025:
Scheme Year | Total Applications Accepted |
2020/21 | 214 |
2021/22 | 222 |
2022/23 | 258 |
2023/24 | 265 |
2024/25 | 259 |
Source: NHSBSA
Notes: These figures do not include NHS staff who are terminally ill but do not meet the criteria for a serious ill-health pension, those who choose to not apply, and those who are not members of the NHS Pension Scheme. Therefore, the numbers of NHS employees with terminal diagnoses who die in employment and retirement may be greater than those set out in the table.
Asked by: John Glen (Conservative - Salisbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 23 July 2025 to Question 68387 on Epilepsy and Pregnancy: Sodium Valproate, whether his Department is taking steps to guarantee that every female valproate patient aged 13-54 received documented counselling and signs the annual risk form before continuing treatment.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
NHS England has worked collaboratively with the Medicines and Healthcare products Regulatory Agency (MHRA) on the safer use of valproate containing medicines.
The Medicines and Pregnancy Registry monitors prescribing of valproate and highlights the number of pregnancies potentially exposed to valproate. The Registry is available at the following link: https://tabanalytics.data.england.nhs.uk/t/Public/views/MedsPreg/TitlePage?%3Aembed=y&%3Aiid=1&%3AisGuestRedirectFromVizportal=y.
This data demonstrates a reduction in prescribing valproate to women and girls as well as a reduction in the number of possible exposed pregnancies since the Pregnancy Prevention Programme (PPP) was introduced in 2018. Analysis shows the implementation of the PPP by ICBs is consistent across the country.
No such guarantee is being pursued. The existing measures described above including the regulatory position is a strong statement of the expected quality of care which is monitored through the Medicines and Pregnancy Registry.
Asked by: John Glen (Conservative - Salisbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 23 July 2025 to Question 68387 on Epilepsy and Pregnancy: Sodium Valproate, whether his Department plans to (a) mandate central tracking and annual reporting on how many women (i) received the Pregnancy Protection Porgramme and (ii) signed the risk acknowledgement form.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
NHS England has worked collaboratively with the Medicines and Healthcare products Regulatory Agency (MHRA) on the safer use of valproate containing medicines.
There are no plans to mandate central tracking and annual reporting on how many women (i) received the Pregnancy Protection Programme and (ii) signed the risk acknowledgement form.
This is because such a measure would not be helpful, at an aggregated and anonymised level without a holistic review of each patient’s clinical and social circumstances. This could only be achieved with a national clinical audit. Such audits are expensive and can only be justified when there is significant room for improvement in outcomes, which is not the case in this instance.
Asked by: John Glen (Conservative - Salisbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when he plans to make a decision on the future of (a) UKHSA Porton Down and (b) the single science hub at Harrow.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
On 17 July 2025, my rt. Hon. Friend, the Secretary of State for Health and Social Care, announced that the Government will proceed with plans to develop new state-of-the-art scientific facilities at Harlow, Essex. The move to Harlow will only affect UK Health Security Agency (UKHSA) staff and therefore anyone on the site employed by the Defence Science and Technology Laboratory will be unaffected.
The Harlow site, with its proximity to the Oxford-Cambridge Investment Corridor, also represents a significant growth opportunity. Moving UKHSA facilities to the area will unlock opportunities for partnerships with industry and academia.
This process will not be immediate. We expect the new site at Harlow to open in stages, beginning in the mid-2030s and concluding by 2038, and therefore given the criticality of the work carried out at both Colindale and Porton Down, these two sites will remain open until that time. UKHSA staff will receive extensive support throughout the next decade on this transition.
Asked by: John Glen (Conservative - Salisbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 9 July 2025 to Question HL9069 on Epilepsy and Pregnancy: Sodium Valproate, how many women prescribed Valproate (a) received the pregnancy prevention programme and (b) signed the acknowledgement of risk form.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
There is no central record of the number of women who have ‘received’ the Pregnancy Prevention Programme, nor whether they have signed the Annual Risk Acknowledgement Form.
Responsibility for the implementation of the new regulatory measures relating to valproate was assigned to integrated care boards (ICBs) in November 2023, via a National Patient Safety alert, which is available at the following link:
ICBs across the country have taken action in response to this alert. The Cheshire and Mersey ICB is a particular exemplar. NHS England monitors primary care prescribing and the exposure to valproate during pregnancy using the Medicines in Pregnancy Registry, with further information available at the following link:
This shows a significant reduction in the number of pregnancies during which valproate may have been taken. In the last six-month reporting period, the data indicates that there were up to 11 pregnancies during which valproate may have been prescribed. This is across a population of approximately 15,000 women between the ages of 13 to 54 years old who are prescribed valproate each month.
Asked by: John Glen (Conservative - Salisbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many children diagnosed with an autistic spectrum disorder also have a diagnosis of foetal valproate syndrome.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Everyone who has been harmed from sodium valproate has our deepest sympathies. Information on the number of children diagnosed with an autistic spectrum disorder and a diagnosis of foetal valproate syndrome is not collected centrally.